A scientific morning related to symptomatic and asymptomatic hyperuricemia and its prevalence in Iran and the world was held on August 27, 2024, in Tehran’s Hasheminezhad Nephrology & Transplantation hospital by Kimiaara Company.
In this meeting, Dr. Rahimi, medical advisor of company, discussed about the treatment protocol for symptomatic hyperuricemia according to the latest ACR guidelines, as well as the prescription of blood uric acid-lowering drugs in hyperuricemic patients without clinical symptoms in high-risk patients, including patients with moderate to severe renal failure , peri dialysis and dialysis, kidney stone and kidney transplant and CVRD and heart failure patients.
This scientific morning was held on Tuesday, August 27, 2024. with the presence of respected professors of nephrology and kidney transplantation:
- Dr. Shahrzad Osare, Head of Nephrology society and nephrology department in hospital.
- Dr. Tahereh Malakootian
- Dr. Fereshteh Sedadi
- Dr. Honaz Akbari
- Dr. Bahareh Marghoob
- Dr. Hooshang Sanadgol
- And also, internal residents.
At the end of this session, precious professors commented on the comparison of the efficacy and safety of febuxostat molecule and its superiority over allopurinol in various hyperuricemic and kidney failure patients.
The febuxostat molecule bioequivalence studies about Febix with Adenoric brand of Menarini company were investigated, and the results show that Febix is therapeutically equivalent to the originator of Menarini company according to the bioequivalence criteria approved by FDA
